We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
SOTYKTU Bristol-Myers Squibb Australia Pty Ltd
Product name
SOTYKTU
Accepted date
Jul-2025
Active ingredients
deucravacitinib
Proposed indication
Sotyktu (deucravacitinib) is proposed for the treatment of adult patients with active psoriatic arthritis, a form of inflammatory arthritis that affects some people with the skin condition psoriasis.
Application type
C (new indication)
Publication date
Jul-2025